ALBACORE-CAPITAL-GRP
13.2.2020 11:02:04 CET | Business Wire | Press release
European credit investment firm AlbaCore Capital Group (“AlbaCore”, “the Firm”), announced the successful close of its second fund, AlbaCore Partners II ICAV (“Fund II”), which has €1.5bn1 in total AUM. The Firm also recently announced plans for a debut CLO in 2020, which is currently in the warehousing phase. AlbaCore’s total AUM now stands at €3.6bn2 across its commingled and customised vehicles. The Firm’s investor base includes pension funds, sovereign wealth funds, endowments, insurance companies, consultants and family office investors, across Europe, North America, Middle East and Asia.
AlbaCore’s strategy focuses on bespoke private credit solutions for larger European companies, with the flexibility to opportunistically invest in secondary and primary markets when relative value is attractive. AlbaCore expects Fund II to be approximately 60% deployed at the end of February, after actively buying in the Q4 2018 credit market sell-off, and more recently shifting focus to primary and private markets. AlbaCore was the sole underwriter for subordinated debt related to two UK public-to-private transactions: BCA Marketplace (LSE: BCA - delisted) and Ei Group (LSE: EIG). Fund II gross IRR for 2019 was +20.6%.3
Bill Ammons, Founding Partner and Portfolio Manager, commented, “Our investing over the past fifteen months demonstrates the value of a flexible mandate in periods of market stress and also periods of resurging positive sentiment, as we saw in the second half of 2019. We are particularly excited about the recent BCA and Stonegate’s acquisition of Ei Group deals, which exemplify AlbaCore’s ability to provide unique, sizeable capital solutions that helped unlock the deals for the sponsor, while also providing an attractive risk/return to our investors.”
AlbaCore has built a 32-person team across its London and Dublin offices, and invests in a capital structure-agnostic manner, via a combination of senior secured loans, high yield bonds, private debt, and preferred equity. AlbaCore’s focus on generating consistent risk-adjusted returns across the capital structure and liquidity spectrum has generated 870bps of gross alpha over European credit markets across its two funds since inception4 .
AlbaCore champions a dynamic ESG approach which is well-integrated into the team’s investment decision making and ongoing risk monitoring. AlbaCore’s maiden CLO will also incorporate AlbaCore’s unique investment process and focus on ESG as part of its credit selection criteria.
Deborah Cohen Malka, Managing Director and Deputy Portfolio Manager, added, “ESG is a critical element of our Firm’s values and investment process. We continue to enhance the manner in which we implement ESG as part of our bottom up credit selection process. We also value our partners’ input to understand and incorporate their ESG ideas so we can continue to be a dynamic leader in credit investing and ESG related issues.”
David Allen, Founder and Chief Investment Officer, concluded: “AlbaCore is delighted and grateful for the opportunity to create new partnerships and expand upon existing relationships as we mature as a firm. We have come a long way since our founding in 2016, and we would not be where we are without our partners. Looking ahead we feel well positioned to continue to deliver strong risk-adjusted returns in 2020. We have an active private market pipeline, and dry powder to be opportunistic as markets digest the recent UK election results and navigate what could be an unpredictable year leading up to the US elections in November. We look forward to active and continued engagement with our partners in the coming year.”
About AlbaCore Capital Group
AlbaCore is a specialist European credit platform focused on European corporate credit markets. Founded in 2016, AlbaCore manages €3.6bn5 of AUM for global pension funds, insurance companies, family offices and endowments. AlbaCore takes a patient, long-term investment approach to private and opportunistic European credit markets. The credit selection process is based on fundamental research with a focus on capital preservation, ESG factors and risk-adjusted returns. Headquartered in London with an office in Dublin, AlbaCore is an organisation built on values, with a partnership approach alongside our investors and counterparties at our core.
____________________
1
AUM is calculated as the sum of the Net Asset Value, undrawn capital commitments and available debt finance for Fund II as of 31 December 2019.
2
AUM is calculated as the sum of the Net Asset Value, undrawn capital commitments and available debt finance of all vehicles managed by AlbaCore.
3
Gross Internal Rate of Return (“IRR”) is calculated using fully equalised cash flows between Fund II and an investor as if all current investors had been committed to Fund II from inception. Rate of return calculated does not include management or performance fees, which would be reflected in a net internal rate of return (that would be lower) actually received by investors. Gross IRR is net of fund level expenses (including the costs of any such subscription line facility), but gross of management fees and performance fees. Past performance is not indicative of future results, which may vary.
4
Alpha generation is based on the gross composite IRR of AlbaCore Partners I ICAV and Fund II from inception of each fund to 31 December 2019 vs the blended IRR, assuming an equal weighting, of BAML Euro High Yield Index and S&P Euro Lev Loans Index as benchmarks for the performance of relative European credit markets.
5
AUM is calculated as the sum of the Net Asset Value, undrawn capital commitments and available debt finance of all vehicles managed by AlbaCore.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200213005099/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kiabi Selects Navan to Centralise Global Travel Program11.5.2026 09:00:00 CEST | Press release
Fashion retailer targets high employee adoption and efficiency with AI-powered travel platform Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced it has been selected by Kiabi, the French multinational fashion retailer, to consolidate its global travel with one unified platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511547434/en/ Fashion retailer targets high employee adoption and efficiency with AI-powered travel platform To support its workforce of nearly 10,000 “Kiabers,” the retailer required a solution capable of providing an easy-to-use travel platform. Navan was selected due to its intuitive AI-powered interface and ability to integrate with Kiabi’s travel policies directly in-app. “Managing travel was becoming an administrative burden that slowed our teams down,” said Denise Maurice, Indirect Procurement Director at Kiabi. “We wanted to give our ‘Kiabers’ the
Owl Labs partners with Westcoast to expand access to seamless hybrid meeting experiences in the UK and Ireland11.5.2026 09:00:00 CEST | Press release
Partnership aims to reduce the ‘meeting tax’ by expanding access to Owl Labs products through Westcoast’s extensive distribution network Owl Labs, a global leader in AI-powered, 360-degree video conferencing solutions, today announced a new UK and Ireland distribution partnership with Westcoast Limited, one of the country’s largest and most trusted IT distributors. The agreement will see Westcoast distribute the full range of Owl Labs’ award-winning Meeting Owl and Owl Bar products across the UK and Ireland, providing greater choice, availability, and dedicated support for resellers and end customers navigating the demands of hybrid work. The partnership aims to address the technical setup challenges that plague meetings across the UK. Owl Labs’ recent State of Hybrid Work report found that nearly 8 in 10 workers (79%) lose time in meetings due to technical difficulties such as connecting to a meeting or setting up a camera. By making Owl Labs’ solutions simpler to source, deploy and s
Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G pTau 217 Plasma Assay11.5.2026 09:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Fujirebio Europe N.V. has obtained a CE certificate of the Lumipulse G pTau 217 Plasma assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human plasma (K2EDTA). “With Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma now CE‑marked on our LUMIPULSE G platform, we are advancing a new era of neurology diagnostics—one where blood‑based biomarkers enable earlier, broader, and more accessible insights into Alzheimer’s disease and neurodegeneration.” said Christiaan De Wilde, CEO at Fujirebio Europe N.V. “By delivering fully automated and scalable solutions, we are helping clinicians move decisively toward more timely and informed decision‑making. This milestone underscores our long‑term vision to reimagine the diagnostic
Mevion Introduces the First Proton Therapy System Designed for a LINAC Vault at ESTRO 202611.5.2026 08:00:00 CEST | Press release
The MEVION S250-FIT™ creates a new pathway for European cancer centers to integrate proton therapy into existing radiotherapy programs Proton therapy is entering the LINAC vault. At ESTRO 2026, Mevion Medical Systems will introduce the MEVION S250-FIT Proton Therapy System to the European radiation oncology community, the first proton therapy system designed for installation in a standard radiation therapy vault. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507172087/en/ The MEVION S250-FIT™ Proton Therapy System Now both U.S. FDA-cleared and CE-marked under Regulation (EU) 2017/745, the S250-FIT creates a new pathway for cancer centers to bring proton therapy into existing LINAC-based treatment environments, aligning advanced proton capability with the infrastructure, workflows, and capital planning of modern radiation oncology. Stanford Medicine: First S250-FIT Installation On April 7, 2026, Stanford Medicine unveiled
Vedanta FY26 Profit Soars by 22% to $2.8 bn; Enters Demerger Phase11.5.2026 02:30:00 CEST | Press release
India-based Vedanta Limited (BSE: 500295 & NSE: VEDL), a global leader in metals, oil & gas, critical minerals, power and technology, announced its results for the fourth quarter and full year ended 31 March 2026. It has delivered its best-ever financial performance, driven by structurally strong businesses and disciplined execution. For the full year, Vedanta’s Profit stood at an all-time high of $2.8 bn, reflecting a 22% YoY increase and a profit of $1 bn in Q4 FY26, up nearly 90% YoY. Vedanta reported its highest-ever annual revenue of about $20 bn, up 15% YoY, with Q4 revenue at $5.6 bn, an increase of nearly 30% YoY. The Company maintained strong cost leadership, contributing to record EBITDA of $6.3 bn for FY26, up by about 30% YoY, with margins expanding to around 40%. Q4 EBITDA stood at $2.0 bn, up by nearly 60% YoY, with a margin of approximately 44%. The balance sheet strengthened further, with Net Debt/EBITDA improving to 0.95x, supported by strong cash generation. Underscor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
